Europe Expansion TD2's expansion into Europe creates a regional hub for oncology translational services, enabling sponsors to leverage EU regulatory know-how and integrated preclinical to clinical support for faster, cross-border trials.

Multi-omics Advantage A partnership with Panome Bio positions TD2 as a partner for biomarker-driven oncology programs, delivering integrated omics data to inform go/no-go decisions and de-risk clinical development.

End-to-End Capabilities Acquisition of Flow Contract Site Laboratory enhances preclinical and translational services, offering seamless progression from bench to clinic and enabling faster program timelines for sponsors.

Leadership & Strategy Strategic leadership hires signal a focus on solutions-led engagements, enabling tailored trial design, portfolio optimization, and improved operational execution for oncology programs.

Oncology Niche A focused expertise in glioblastoma and non-small cell lung cancer with early-stage collaborations and scientific outreach demonstrates depth in precision preclinical and early clinical work, appealing to biotech startups and mid-market sponsors.